Exelixis Files US Application For Expanded Use Of Cabometyx In Patients 12+ Years With Thyroid Cancer

The FDA has accepted Exelixis Inc's EXEL supplemental marketing application seeking approval for Cabometyx (cabozantinib) for differentiated thyroid cancer (DTC).
The application under priority review covers patients 12 years and older who have progressed following prior therapy and are radioactive iodine-refractory (if radioactive iodine is appropriate).
The agency action date is December 4, 2021.
Price Action: EXEL shares are down 1.40% at $17.03 during the market session on the last check Thursday.
Related content: Benzinga's Full FDA Calendar.